Maximum Daily Dose of Pregabalin
The maximum daily dose of pregabalin is 600 mg/day, administered as either 200 mg three times daily or 300 mg twice daily, with dose reduction required in patients with renal impairment. 1
Dosing by Indication
The FDA-approved maximum dose is consistent at 600 mg/day across indications, though the recommended therapeutic doses vary 1:
Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
- Maximum dose: 300 mg/day (100 mg three times daily)
- Start at 50 mg three times daily (150 mg/day)
- May increase to 300 mg/day within 1 week
- Important caveat: Although pregabalin was studied at 600 mg/day, there is no evidence this dose provides additional significant benefit, and it was less well tolerated 1
- Treatment with doses above 300 mg/day is not recommended for this indication 1
Postherpetic Neuralgia
- Maximum dose: 600 mg/day (300 mg twice daily or 200 mg three times daily)
- Start at 75 mg twice daily or 50 mg three times daily (150 mg/day)
- Increase to 300 mg/day within 1 week
- For patients tolerating 300 mg/day but with inadequate pain relief, may titrate to 600 mg/day 1
- Reserve doses above 300 mg/day only for patients with ongoing pain who tolerate 300 mg daily, due to higher adverse event rates 1
Partial-Onset Seizures (Adults)
- Maximum dose: 600 mg/day
- Start at 150 mg/day
- Administer in 2 or 3 divided doses 1
Fibromyalgia
- Maximum dose: 450 mg/day (225 mg twice daily)
- Start at 75 mg twice daily (150 mg/day)
- Increase to 300 mg/day within 1 week
- May increase to 450 mg/day based on efficacy and tolerability 1
Clinical Practice Considerations
Guideline recommendations align with FDA labeling, specifying 600 mg/day as the maximum dose (200 mg three times daily or 300 mg twice daily), with mandatory dose reduction in renal impairment 2. The guidelines emphasize that higher doses are not consistently more effective than 300 mg/day and are associated with greater adverse effects 2.
Key Safety Points
Dose-dependent adverse effects are the primary limitation:
- Dizziness and somnolence are most common, typically emerging within the first week of treatment 3
- Weight gain appears 6-8 weeks after treatment initiation 3
- Higher doses (>300 mg/day) increase discontinuation rates due to adverse events 2
Renal Impairment
Mandatory dose adjustment is required for creatinine clearance <60 mL/min, as pregabalin is eliminated primarily by renal excretion 2, 1. Failure to adjust doses in renal impairment significantly increases adverse event risk.
Regional Differences
There is a notable discrepancy between US and European Union approvals: the US FDA approves a maximum of 300 mg/day for diabetic peripheral neuropathy, while the EU approves up to 600 mg/day 4. However, clinical data consistently show that doses >300 mg/day provide minimal additional benefit with increased adverse effects for neuropathic pain conditions 2, 4.
Discontinuation
Taper gradually over a minimum of 1 week when discontinuing pregabalin to minimize withdrawal symptoms 1.